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ABSTRACT
Objective: To know the relationship between p53 expression and prostate specific antigen (PSA) serum level in prostate 
cancer patients. Material & method: Specimens were studied from patients with pathological diagnosis of prostate cancer 
in Sardjito Hospital Yogyakarta during 2007 to 2008. The p53 expression was measured by immunohistochemical staining. 
The stains were done in Department of Anatomical Pathology and examined by a pathologist. The relationship between p53 
mutated expression and PSA serum level were analyzed with correlation coefficient (rs). Results: There were 29 patients 
included in this study. The mean age was 66,34 ± 8,15 (50 - 83) years old. The mean PSA serum level was 165,98 ± 269,208 
(1,4 – 1051) ng/ml. The mean number of p53 expression was 111,38 ± 94,30 (16 – 396). There was positive correlation 
between p53 expression and increasing PSA serum level in the prostate cancer patients (rs + 0,497; p = 0,006). 
Conclusion: P53 expression was positively correlated with increasing PSA serum level.
Keywords: Prostate cancer, p53 expression, PSA serum level.
ABSTRAK
Tujuan Penelitian: Mengetahui hubungan antara ekspresi p53 dengan kadar serum prostate specific antigen (PSA) pada 
pasien kanker prostat. Bahan & Cara: Sampel penelitian berasal dari pasien yang terdiagnosis secara klinis dan 
histopatologis menderita kanker prostat di RS Dr. Sardjito Yogyakarta periode 2007–2008. Ekspresi p53 diketahui dengan 
pengecatan imunohistokimia. Pengecatan dilakukandi Departemen Patologi Anatomi dan diperiksa oleh seorang Patolog. 
Hubungan antara ekspresi p53 dan kadar serum PSA dianalisa dengan koefisien korelasi Spearman (rs). Hasil Penelitian: 
Terdapat 29 pasien dalam penelitian ini. Usia rerata pasien adalah 66,34 + 8,15 (50-83) years old. Rerata kadar serum 
PSA adalah 165,98 + 269,208 (1,4–1051) ng/ml. Rerata ekspresi p53 adalah 111,38 + 94,30 (16–396). Terdapat hubungan 
positif antara ekspresi p53 dengan kadar PSA serum (rs + 0,497; p = 0,006). Simpulan: Terdapat hubungan positif antara 
ekspresi p53 dengan kadar serum PSA.
Kata Kunci: Kanker prostat, ekspresi p53, kadar serum PSA.
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INTRODUCTION
Prostate specific antigen (PSA) is a 34 kD 
glycoprotein produced by the prostate gland. PSA is 
produced by the secretory glands and epithelial cells 
lining the periurethral glands. In normal prostate 
tissue PSA is secreted into the lumen of secretory 
duct of the gland and only a small amount that enters 
the systemic circulation. PSA serves for semen 
liquefaction so that spermatozoa can move easily 
and also serves to shed mucosal layer of uterine 
1cervix.
Increased PSA serum occurs in benign 
prostate enlargement, prostatitis, other benign 
prostatic disorders and prostate cancer. Elevated 
levels of serum PSA is a good predictor of prostate 
2cancer.  Prostate cancer does not produce more PSA 
than normal prostate gland cells but elevated levels 
of PSA serum in prostate cancer is caused by the 
3damage in normal architecture of the prostate gland.  
However, an increase in PSA production is found in 
metastatic prostate cancer. Increased PSA 
production was not yet clearly known but it is 
believed to be related to the gene p53 suppression by 
4mutant p53 gene.
P53 is a protein with a molecular weight of 
53 kD produced by a gene on chromosome 17p, 
which is essential in multicellular organisms 
because p53 plays a role in the regulation and control 
3of cell proliferation.  Under conditions of DNA 
damage in a cell, the functional p53 stops cell 
division in G1 phase or stimulates cell intrinsic 
mechanism for the occurrence of cell apoptosis. 
Because of this role, p53 is known as a tumor 
suppressor. The loss of p53 function will result in 
uncontrolled growth of cells with damaged genetic 
5material.  In normal cells p53 binds to DNA that 
would stimulate other genes in the DNA to produce 
p21 protein, and p21 protein will bind to the cell 
division booster protein (cdk2 protein). When the 
p21 protein and cdk2 complex is formed, it will stop 
cell division. If p53 gene mutation occurs, then p53 
will not bind to DNA. The consequences are the loss 
of p21 protein formation and the loss of control of 
6cell division.
In addition to DNA damage, p53 activation 
can occur in a state of stress on cells caused by 
exposure to chemicals, ultraviolet and radioactive. 
In normal cells p53 is kept low due to the process of 
p53 degradation. A protein called MDM2 binds to 
p53. This protein will carry the p53 protein into the 
4cytosol and be degraded by the proteosome enzyme.
Figure 1. Physiology of p53 in the regulation of normal 
cell division.
Mutation of the p53 gene is the most 
frequent changes found in malignant prostate cancer 
in human organs. In prostate cancer the expression of 
mutant p53 is increasing in advanced stage. P53 
mutations are associated with resistance to chemo-
therapy, gene instability, increased angiogenesis and 
rapid tumor progression. P53 mutation is rare in 
localized prostate cancer. In a research conducted by 
Gurova et al (2002) on mutant p53 gene, the PSA-
expressing gene had increased 6-8 fold, so it was 
suspected that elevated PSA levels is associated with 
7mutant p53 expression.
OBJECTIVE
This study aimed to explore the relationship 
between the expression of p53 mutants with 
increased PSA serum levels in patients with prostate 
cancer.
MATERIAL & METHOD
Subjects of this study were all patients with 
prostate adenocarcinoma who were diagnosed 
clinically and histopathologically in the period 
between January 1, 2007 and December 31, 2008 at 
Dr. Sadjito Hospital, Yogyakarta.
The patients must meet the following 
inclusion criteria (1) Patients with prostate 
adenocarcinoma that had been established based on 
histopathologic examination, (2) The clinical 
staging of patients had been recognized and 
confirmed by a urologist (AJCC-TNM, 1992), (3) 
preoperative serum PSA levels was examined, and 
(4) the degree of tumor differentiation had been 
recognized (Gleason score).
The exclusion criteria in this study were 
incomplete preoperative PSA serum data and clinical 
staging of patients in the medical record.
PSA serum level was checked in the 
Laboratory of Clinical Pathology, Dr. Sardjito 
Hospital, and data may be found in the patient's 
medical record.
P53 staining procedure was performed in the 
Laboratory of Anatomic Pathology, Dr. Sardjito 
Hospital, using anti-p53 monoclonal antibodies D-
07. This antibody binds to normal p53 protein and 
p53 mutants, but because normal p53 protein will be 
degraded, so that only mutant p53 will bind to this 
antibody and will be microscopically visible. P53 
expression is examined by one anatomic pathologist 
by counting the number of nuclei containing p53 in 
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P53 
expression 
t-PSA serum 
value (ng/ml) 
Spearman's rho P53 Expression Correlation Coefficient 1,000 ,497(**) 
Sig. (2-tailed) , ,006 
N 29 29 
t-PSA serum value (ng/ml) Correlation Coefficient ,497(**) 1,000 
Sig. (2-tailed) ,006 , 
N 29 29 
each preparation. Examination of each preparation 
was carried out in five visual fields and the result was 
the mean of those five visual fields.
Correlation between p53 expression with 
preoperative PSA serum levels was statistically 
analyzed by means of bivariate analysis. Prior to 
analysis, data normality test was performed with the 
technique of one-sample Kolmogorov-Smirnov. If 
the obtained data were normally distributed, 
bivariate analysis was performed with Pearson 
correlation test, but if the data were not normally 
distributed, Spearman correlation test would be 
used. Data analyses were performed with statistical 
analysis program SPSS version 16.0.
RESULTS
There were 29 males involved as subjects, 
with mean age of 66,34 ± 8,15 (50-83) years. They 
met the criteria and were included as research 
subjects. Characteristics of the subjects can be seen 
in Table 1. The mean preoperative PSA serum levels 
were 165,98 ± 269,2 (1,4 to 1051) ng/ml and the 
mean number of p53 expression was 111,38 ± 94,3 
(16-396)/LPB.
Table 1. Characteristics of patients (n = 29).
  
 
Age (year), mean + SD (interval) 66,34 + 8,15 
PSA serum value (ng/ml) 
0 - 9   
10 - 19   
20 - 49   
> 49 
 
2 (6,9%) 
1 (3,4%) 
4 (13,8%) 
22 (75,9%) 
Table 2. Staging of prostate cancer patients.
 
 
Staging Total 
Localized prostate cancer 14 (48,3%) 
Locally advanced prostate cancer 
(T3 -T4, Nx -N0,M0)
0 (0%)
 
Metastatic prostate cancer (M1) 
 
15 (51,7%) 
(T1-2, Nx -N M0) 0,
 
Figure 1. Expression of p53 in the study sample.
Figure 2. Results of pathological examination of 
samples with low p53 expression.
Figure 3. Results of pathological examination of 
samples with high p53 expression.
Table 3. Correlation analysis.
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Because the results of normality test with 
Kolmogorov-Smirnov showed that the data were not 
normally distributed (r = 0,000), Spearman corre-
lation test was carried out. The analysis showed that 
there was a significant positive correlation between 
p53 expression with increased levels of preoperative 
PSA serum (Spearman r = + ,497; p = 0,006).
DISCUSSION
Mutation of the p53 tumor suppressor gene 
is the most frequent genetic alterations found in 
human malignant tumors and its presence can be 
8detected by immunohistochemical staining.  P53 
plays an important role in the regulation of cell 
proliferation, so that the occurrence of p53 mutations 
may become one marker of abnormal cell 
proliferation. Some studies show that expression of 
p53 are found in patients with metastatic and 
9hormone refractory prostate cancer.
In prostate cancer, PSA has been used as a 
progression marker because of elevated PSA is 
sensitive enough as an indicator of relapse and the 
incidence of metastases after treatment, so it is 
interesting to find the correlation between elevated 
PSA with prostate cancer proliferation activity. One 
of this effort is by measuring the expression of 
10mutant p53.
This study found significant correlation (p = 
0,006) between increased expression of p53 mutants 
and increased PSA serum levels. This is consistent 
with the research conducted by Gurova et al (2002). 
PSA levels increased because among mutant p53 
genes there are gene pieces that play a role as PSA 
promoter. However, this is found primarily in 
7prostate cancer metastases and hormone refractory.  
In early stages, the increase of PSA in prostate cancer 
occurs due to the damage to the normal architecture 
of the prostate gland, but when p53 mutations occur, 
PSA will rise 6-8 fold due to abnormal production of 
7the PSA.  
The results of this study contradict those 
found by Papadopoulos et al (1996) who disclosed 
that there was no relationship between PSA serum 
5levels with the expression of p53,  but the 
explanation of this finding was that because the 
study samples were taken from localized patients 
and locally advanced prostate cancer without 
metastases. Whereas, p53 expression is associated 
with elevated levels of PSA serum occurs in prostate 
7cancer metastasis or hormone refractory.
CONCLUSION
There is a significant relationship between 
p53 expression and increased PSA levels. This 
relationship is primarily seen in prostate cancer 
metastasis. 
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